HCW11-006HCW11-006-treatedBCGNSG mouse modelbladder cancer modelEG7-OVA tumor model
…unctionality, and synergizes with immune checkpoint inhibitors. HCW11-006 represents a promising immunotherapeutic agent capable of induc…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Funders
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentions29,499matching articles
244,054matching entity mentions
30popular entities listed
0%of mentions human-reviewed
Popular entities in these results
Choose an entity to see the articles in which it was identified.
EMBASE784PUBMED717COVID-19645Cancer605SLE570Diabetes552NHS522WEB OF SCIENCE499Hypertension418SCOPUS417HIV406Systemic Lupus Erythematosus390Heart Failure364Asthma349Stroke336COPD331WHO330Colorectal Cancer327Cardiovascular Disease317Type 2 Diabetes316Chronic Obstructive Pulmonary Disease313Joanna Briggs Institute306MEDLINE306Atrial Fibrillation283Cochrane Library275Breast Cancer271Hepatocellular Carcinoma253SSc251Inflammatory Bowel Disease250Obesity246
Matching articles
29,499 articles · page 243 of 2459melanomaUniversity Medical Center Hamburg-Eppendorfendometrial canceresophageal cancerhead & neck squamous cell carcinomasolid tumorslung squamous cell carcinomatriple negative breast cancerovarian epithelial cancerovarian carcinoma+1 more
…nd 38 melanoma patients.Results PRAME prevalence was highest in melanoma, endometrial cancer, ovarian epithelial cancer, lung squamous c…
98.8%
cancerautoimmunityfibrosisChronic inflammatory disorders
…exhibited potent and durable anti-tumor activity. In an ovarian cancer model, adjuvant administration of uPAR CAR T cells post-surgica…
98.3%
AB-3028mCRPCsolid tumorsTCGAhematological malignanciesmetastatic castration-resistant prostate cancer (mCRPC)The Cancer Genome Atlasprostate tumorsGTExChimeric Antigen Receptor T (CAR T) cell therapies
…al persistence.Methods To evaluate suitable target antigens for AB-3028, we first conducted a comprehensive in silico analyses with bul…
Ovarian cancerGeorge Washington UniversityOCOC-expandedOC-specificimmune checkpoint blockade therapyneuroblastoma
…Background Ovarian cancer (OC) is the most lethal gynecological malignancy. The majority …
pembrolizumabUSC Norris Comprehensive Cancer CentercetuximabLos Angeles General Medical CenterSinonasal malignanciessquamous cell carcinomaSNSCC
…) or unknown (30.8%, 53.8%). The most common ICI agent used was pembrolizumab (92.3%), with 7 patients receiving ICI as a first-line systemic…
mccRCCnivolumabpembrolizumabcabozantiniblenvatinibipilimumabaxitinibICI rechallenge
…esent the backbone first-line treatment for patients (pts) with mccRCC. While multiple ICI-based regimens are approved in the metastat…
cancerRuxolitinibCmpd1hodgkin lymphomaB16 melanomaTBK1C57BL/6 mice
…f interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell. 2019;178(4):933–948.e14.Wong …
nivolumabSingapore General HospitalipilimumabcobolimabTNBC
… humanized mice models treated with immunotherapy combinations (nivolumab, ipilimumab, cobolimab)-coupled LSD1 inhibitor significantly re…
atezolizumabbevacizumabatezolizumab-containingHigh-grade serous ovarian canceraspirinPROCEORTC-1508GCGlow-dose aspirinPD-L1 blockadeplatinum-resistant ovarian cancer+1 more
…with PD-L1 blockade. The EORTC-1508GCG phase II trial evaluated atezolizumab (anti-PD-L1), bevacizumab (anti-VEGF), and low-dose aspirin in …
ZM008PembrolizumabZM008-001Advanced Solid Tumors
…tribution of immune and tumor cells in the TME as a response to ZM008 treatment. Key inclusion criteria: histologically confirmed adv…
LEU011solid tumorssolid tumoursLEU01101ClinicalTrials.govlymphodepleting chemotherapyLDCNorth East - York Research Ethics Committee
…ical stage NKG2D-based linear CAR. The trial hypothesis is that LEU011, combined with lymphodepleting chemotherapy (LDC), will be safe…